Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elacestrant + everolimus
- Development stage
- Phase 3
- Lead developer
- Stemline Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of elacestrant and everolimus is being investigated as a treatment for estrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (mBC). This combination aims to address resistance mechanisms in patients who have progressed on prior endocrine therapy and CDK4/6 inhibitors.
02
Targets
ESR1 (ERα)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on elacestrant + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elacestrant + everolimus.